

## Scientific and Technical Information Center

4E12  
If more than one search is submitted, please prioritize searches in order of need.


unity of the invention. Define any terms that may have a special meaning. Give examples of relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract

ARYLSULFONYL-2 (Substituted methyl)propionic acid  
Title of Invention: derivatives as matrix metalloproteinase


\* Inventors (please provide full names): SERGIO MANTEGAM I Annunziata

Earliest Priority Filing Date: 7/5/1999

*\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



SYNTHESIS see claims 4-5



\*\*\*\*\*

**STAFF USE ONLY**

Searcher: Shannon

Searcher Phone #: 308-4499

Searcher Location: \_\_\_\_\_

Date Searcher Picked Up: \_\_\_\_\_

Date Completed: 10/21/02

**Searcher Prep & Review Time:**

Clerical Prep Time: \_\_\_\_\_

Online Time: \_\_\_\_\_

### Type of Search

NA Sequence (#)\_\_\_\_\_

AA Sequence (#)

Structure (#) \_\_\_\_\_

### Bibliographic

## Litigation

Fulltext

Patent Family \_\_\_\_\_

Other \_\_\_\_\_

**Vendors and cost where applicable**

STN

## Dialog

Questel/Orbit

Dr.Link

Lexis/Nexis

## Sequence Systems

WWW/Internet

Other (specify) \_\_\_\_\_

=&gt; fil hcaplus

FILE 'HCAPLUS' ENTERED AT 17:03:36 ON 21 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Oct 2002 VOL 137 ISS 17

FILE LAST UPDATED: 20 Oct 2002 (20021020/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.






CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=&gt;

=&gt;

=&gt; d stat que 18

L1 STR



REP G1=(0-1) N

VAR G2=16/18/21/24/25/27/29/31/32

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE

L5 241 SEA FILE=REGISTRY SSS FUL L1

L6 STR



REP G1=(0-1) N

VAR G2=16/18/21/24/25/27/29/31/32

VAR G3=39/46/47/48

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE

L7 100 SEA FILE=REGISTRY SUB=L5 SSS FUL L6

L8 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L7

=>

=>

=> d ibib abs hitstr l8 1-3

L8 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:396841 HCAPLUS

DOCUMENT NUMBER: 135:5449

TITLE: Preparation of (R)-3-(4-chlorobiphenylsulfonyl)-2-hydroxy-2-(phenylthio)methylpropionic acid and its use as a matrix metalloproteinase inhibitor in the treatment of cancer

INVENTOR(S): Bissolino, Pierluigi; Mantegani, Sergio; Orzi, Fabrizio; Jabes, Daniela; Alzani, Rachele; D'anello, Matteo; Perrone, Ettore

PATENT ASSIGNEE(S): Pharmacia & Upjohn S.P.A., Italy

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001038301	A1	20010531	WO 2000-EP10837	20001101

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 1999-27453 A 19991119

OTHER SOURCE(S): CASREACT 135:5449

AB (R)-3-(4-chlorobiphenylsulfonyl)-2-hydroxy-2-(phenylthio)methylpropionic acid and its salts, useful as a matrix metalloproteinase inhibitor in the treatment of cancers, is prepd. along with its salts.


IT **226419-98-3P 341498-84-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(in the prepn. of (R)-3-(4-chlorobiphenylsulfonyl)-2-hydroxy-2-(phenylthio)methylpropionic acid and its salts as matrix metalloproteinase inhibitors useful in the treatment of cancers)

RN 226419-98-3 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 341498-84-8 HCAPLUS


CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, (2R)-, compd. with (.alpha.S)-.alpha.-[(1R)-1-(methylamino)ethyl]benzenemethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 341498-83-7

CMF C22 H19 Cl O5 S2

Absolute stereochemistry. Rotation (+).




CM 2

CRN 321-98-2

CMF C10 H15 N O

Absolute stereochemistry. Rotation (+).




IT 341498-83-7P 341498-89-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of (R)-3-(4-chlorobiphenylsulfonyl)-2-hydroxy-2-  
 (phenylthio)methylpropionic acid and its salts as matrix  
 metalloproteinase inhibitors useful in the treatment of cancers)

RN 341498-83-7 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-  
 [(phenylthio)methyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 341498-89-3 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-  
 [(phenylthio)methyl]-, monosodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 341498-92-8P 341498-95-1P 341498-98-4P

341499-01-2P 341499-04-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of (R)-3-(4-chlorobiphenylsulfonyl)-2-hydroxy-2-(phenylthio)methylpropionic acid and its salts as matrix metalloproteinase inhibitors useful in the treatment of cancers)

RN 341498-92-8 HCAPLUS


CN L-Arginine, mono[(2R)-3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]propanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 341498-83-7

CMF C22 H19 Cl O5 S2

Absolute stereochemistry. Rotation (+).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 341498-95-1 HCAPLUS  
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, (2R)-3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]propanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 341498-83-7  
 CMF C22 H19 Cl O5 S2


Absolute stereochemistry. Rotation (+).



CM 2


CRN 6284-40-8  
 CMF C7 H17 N O5

Absolute stereochemistry.



RN 341498-98-4 HCAPLUS  
 CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, monopotassium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● K

RN 341499-01-2 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, calcium salt (2:1), (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 1/2 Ca

RN 341499-04-5 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, magnesium salt (2:1), (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● 1/2 Mg

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:63965 HCAPLUS

DOCUMENT NUMBER: 134:131252

TITLE: Preparation of 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivatives as matrix metalloproteinase inhibitors

INVENTOR(S): Mantegani, Sergio; Abrate, Francesca; Bissolino, Pierluigi; Cremonesi, Paolo; Perrone, Ettore; Jabes, Daniela

PATENT ASSIGNEE(S): Pharmacia and Upjohn Spa, Italy

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005756	A1	20010125	WO 2000-EP6429	20000707
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1200398	A1	20020502	EP 2000-954443	20000707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: GB 1999-16562 A 19990714  
WO 2000-EP6429 W 20000707

OTHER SOURCE(S): MARPAT 134:131252


AB 3-Arylsulfonyl-2-methylpropanoic acid derivs. R2CH2CH(COX)CH2SO2C6H4R1-4 [I, X = HONH, HO; R1 = Ph, 4-chlorophenyl, 4-fluorophenyl, 4-cyanophenyl, benzamido substituted benzamido; R2 = SAr, SCH2Ar, OAr, SHet, SCH2Het (Het is a heterocyclic ring), 2,5-dioxo-1-imidazolidinyl, 2,4-dioxo-1-imidazolinyl], having potent and selective inhibitory activity against matrix metalloproteinases, were prepd. E.g., 3-[(4-chloro[1,1'-biphenyl]-

4-yl)sulfonyl]-2-[(phenylsulfanyl)methyl]propanoic acid was prepd.  
Inhibition of MMP-1 and MMP-2 by I was measured.


IT 321584-39-8P 321584-41-2P 321584-44-5P  
321584-46-7P 321584-48-9P 321584-50-3P  
321584-51-4P 321584-54-7P 321584-56-9P  
321584-58-1P 321584-60-5P 321584-62-7P  
321584-64-9P 321584-70-7P 321584-72-9P  
321584-74-1P 321584-76-3P 321584-78-5P  
321584-82-1P 321584-84-3P 321584-86-5P  
321584-88-7P 321584-90-1P 321584-92-3P  
321584-94-5P 321584-96-7P 321584-98-9P  
321585-00-6P 321585-02-8P 321585-04-0P  
321585-10-8P 321585-12-0P 321585-14-2P  
321585-16-4P 321585-18-6P 321585-20-0P  
321585-22-2P 321585-24-4P 321585-26-6P  
321585-28-8P 321585-30-2P 321585-32-4P  
321585-34-6P 321585-36-8P 321585-38-0P  
321585-40-4P 321585-42-6P 321585-45-9P  
321585-47-1P 321585-49-3P 321585-51-7P  
321585-54-0P 321585-56-2P 321585-58-4P  
321585-60-8P 321585-62-0P 321585-64-2P  
321585-66-4P 321585-68-6P 321585-70-0P  
321585-72-2P 321585-74-4P 321585-76-6P  
321585-78-8P 321585-80-2P 321585-82-4P  
321585-84-6P 321585-86-8P 321585-88-0P  
321585-90-4P 321585-92-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivs. as matrix metalloproteinase inhibitors)

RN 321584-39-8 HCAPLUS  
CN Propanoic acid, 2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(phenylthio)- (9CI) (CA INDEX NAME)



RN 321584-41-2 HCAPLUS  
CN Propanoic acid, 2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(phenylthio)-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 321584-44-5 HCAPLUS  
CN Propanoic acid, 2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-


(phenylthio)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321584-46-7 HCAPLUS


CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)




RN 321584-48-9 HCAPLUS

CN 1-Imidazolidinepropanoic acid, .alpha.-[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 321584-50-3 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[ (4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-3,4,4-trimethyl-2,5-dioxo-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 321584-51-4 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[ (1,1'-biphenyl)-4-ylsulfonyl)methyl]-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 321584-54-7 HCAPLUS  
 CN 1-Imidazolidinepropanamide, .alpha.-[[ (4'-chloro[1,1'-biphenyl]-4-

yl)sulfonylmethyl]-N-hydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 321584-56-9 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 321584-58-1 HCAPLUS  
 CN 1-Imidazolidinepropanamide, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-N-hydroxy-4,4-dimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 321584-60-5 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 321584-62-7 HCAPLUS  
 CN 1-Imidazolidinepropanamide, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-N-hydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 321584-64-9 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, 3-butyl-.alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-2,5-dioxo- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 321584-70-7 HCAPLUS  
 CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[(4-hydroxyphenyl)thio]methyl)- (9CI) (CA INDEX NAME)




RN 321584-72-9 HCAPLUS  
 CN Propanoic acid, 2-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-phenoxy-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 321584-74-1 HCAPLUS  
CN 1-Imidazolidinepropanoic acid, 3-butyl-.alpha.-[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 321584-76-3 HCAPLUS  
CN Propanoic acid, 2-[[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(phenylthio)- (9CI) (CA INDEX NAME)




RN 321584-78-5 HCAPLUS

CN Propanoic acid, 2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(2-pyridinylthio)- (9CI) (CA INDEX NAME)




RN 321584-82-1 HCAPLUS

CN Propanoic acid, 2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(2-pyrimidinylthio)- (9CI) (CA INDEX NAME)




RN 321584-84-3 HCAPLUS

CN Propanoic acid, 3-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 321584-86-5 HCAPLUS

CN Propanoic acid, 2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-[(1-methyl-1H-1,2,4-triazol-5-yl)thio]- (9CI) (CA INDEX NAME)




RN 321584-88-7 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[[1-methyl-1H-imidazol-2-yl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 321584-90-1 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[[2,6-dimethyl-4-pyrimidinyl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 321584-92-3 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[[4,6-dimethyl-2-pyrimidinyl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 321584-94-5 HCAPLUS

CN Propanoic acid, 2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(2-thiazolylthio)- (9CI) (CA INDEX NAME)




RN 321584-96-7 HCAPLUS

CN Propanoic acid, 2-[[[(4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 321584-98-9 HCAPLUS

CN Propanoic acid, 3-[4-(acetylamino)phenoxy]-2-[[4-(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 321585-00-6 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[[1,4-dihydro-6-methyl-4-oxo-2-pyrimidinyl]thio]methyl]- (9CI) (CA INDEX NAME)




RN 321585-02-8 HCAPLUS

CN Propanoic acid, 2-[[4-(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-[(1-methyl-1H-tetrazol-5-yl)thio]- (9CI) (CA INDEX NAME)




RN 321585-04-0 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[[2-(hydroxymethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 321585-10-8 HCAPLUS

CN Propanoic acid, 2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]- (9CI) (CA INDEX NAME)



RN 321585-12-0 HCAPLUS


CN Propanoic acid, 3-(1H-benzimidazol-2-ylthio)-2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 321585-14-2 HCAPLUS

CN Propanoic acid, 2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(phenylthio)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 321585-16-4 HCAPLUS

CN 1-Imidazolidinepropanoic acid, .alpha.-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3,4,4-trimethyl-2,5-dioxo-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 321585-18-6 HCAPLUS  
 CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-[(4-hydroxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 321585-20-0 HCAPLUS  
 CN Propanoic acid, 2-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonylmethyl]-3-phenoxy- (9CI) (CA INDEX NAME)



RN 321585-22-2 HCAPLUS  
 CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-(phoxymethyl)- (9CI) (CA INDEX NAME)




RN 321585-24-4 HCAPLUS  
 CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-[(2-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)




RN 321585-26-6 HCAPLUS  
 CN Propanoic acid, 2-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonylmethyl]-3-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)






RN 321585-28-8 HCAPLUS

CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-[[2-pyridinylmethyl]thio]methyl- (9CI) (CA INDEX NAME)




RN 321585-30-2 HCAPLUS

CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl- (9CI) (CA INDEX NAME)




RN 321585-32-4 HCAPLUS

CN Propanoic acid, 2-[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-[[1-(phenylmethyl)-1H-tetrazol-5-yl]thio]- (9CI) (CA INDEX NAME)




RN 321585-34-6 HCAPLUS

CN Propanoic acid, 2-[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-[[5-phenyl-1,3,4-oxadiazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 321585-36-8 HCAPLUS

CN Propanoic acid, 2-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(3-phenyl-1,2,4-oxazol-5-ylthio)- (9CI) (CA INDEX NAME)




RN 321585-38-0 HCAPLUS

CN Propanoic acid, 2-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)




RN 321585-40-4 HCAPLUS

CN Propanoic acid, 2-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(4-methyl-2-oxazolylthio)- (9CI) (CA INDEX NAME)



RN 321585-42-6 HCAPLUS


CN Propanoic acid, 2-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(oxazolo[4,5-d]pyrimidin-2-ylthio)- (9CI) (CA INDEX NAME)



RN 321585-45-9 HCAPLUS


CN Propanoic acid, 3-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[(1,4-tetrazolo[1,5-b]pyridazin-6-ylthio)- (9CI) (CA INDEX NAME)

dihydro-6-hydroxy-4-oxo-2-pyrimidinyl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 321585-47-1 HCAPLUS  
CN Propanoic acid, 2-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(1H-purin-6-ylthio)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 321585-49-3 HCAPLUS  
CN Propanoic acid, 3-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-2-[(3-fluorophenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 321585-51-7 HCAPLUS  
 CN Propanoic acid, 3-[2-(acetylamino)phenoxy]-2-[[4-(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 321585-54-0 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[4-(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 321585-56-2 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[ (4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-3-ethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 321585-58-4 HCAPLUS  
 CN 1-Imidazolidinepropanamide, 3-butyl-.alpha.-[[ (4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-N-hydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 321585-60-8 HCAPLUS  
 CN 1-Imidazolidinepropanamide, 3-butyl-.alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-N-hydroxy-2,4-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 321585-62-0 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-5-(1-methylethyl)-2,4-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 321585-64-2 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-5-(hydroxymethyl)-2,4-dioxo- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A


Cl

RN 321585-66-4 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-5-(hydroxymethyl)-3-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 321585-68-6 HCAPLUS  
 CN Propanoic acid, 2-[[[4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(phenylthio)- (9CI) (CA INDEX NAME)




RN 321585-70-0 HCAPLUS  
 CN Propanamide, 3-[[[4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)




RN 321585-72-2 HCAPLUS

CN Propanoic acid, 2-[[4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 321585-74-4 HCAPLUS

CN Propanamide, 3-[[4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)




RN 321585-76-6 HCAPLUS

CN Propanamide, 3-[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 321585-78-8 HCAPLUS


CN Propanamide, 3-[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 321585-80-2 HCAPLUS


CN Propanoic acid, 3-[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]-2-[(3-

fluorophenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 321585-82-4 HCAPLUS

CN Propanoic acid, 3-[2-(acetylamino)phenoxy]-2-[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 321585-84-6 HCAPLUS

CN Propanoic acid, 2-[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(2-pyridinylthio)- (9CI) (CA INDEX NAME)



RN 321585-86-8 HCAPLUS


CN Propanoic acid, 2-[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 321585-88-0 HCAPLUS

CN 1-Imidazolidinepropanoic acid, 3-butyl-.alpha.-[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 321585-90-4 HCAPLUS  
 CN 1-Imidazolidinepropanamide, 3-butyl-.alpha.-[[[(4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-N-hydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A


CN

IT 321586-57-6P 321586-68-9P 321586-72-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. of 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivs.  
 as matrix metalloproteinase inhibitors)


RN 321586-57-6 HCAPLUS

CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl]thio]methyl]-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 321586-68-9 HCAPLUS  
 CN Propanoic acid, 2-[[[4'-chloro[1,1'-biphenyl]-4-yl)thio]methyl]-3-phenoxy-  
 (9CI) (CA INDEX NAME)




RN 321586-72-5 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, 3-butyl-.alpha.-[[[4'-chloro[1,1'-biphenyl]-  
 4-yl)thio]methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:354468 HCAPLUS

DOCUMENT NUMBER: 131:18833

TITLE: Preparation of .alpha.-hydroxy, -amino, and halo derivatives of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors

INVENTOR(S): Warpehoski, Martha A.; Mitchell, Mark Allen; Harper, Donald E.; Maggiora, Linda Louise

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9926909	A2	19990603	WO 1998-IB2154	19981118

WO 9926909 A3 19990826

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2310401 AA 19990603 CA 1998-2310401 19981118

AU 9925405 A1 19990615 AU 1999-25405 19981118

EP 1037868 A2 20000927 EP 1998-966869 19981118

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 9814699 A 20001003 BR 1998-14699 19981118

JP 2001524462 T2 20011204 JP 2000-522069 19981118

US 6437177 B1 20020820 US 1998-196190 19981120


NO 2000002505 A 20000630 NO 2000-2505 20000515

PRIORITY APPLN. INFO.: US 1997-72655P P 19971121

WO 1998-IB2154 W 19981118

OTHER SOURCE(S): MARPAT 131:18833

GI



AB The title compds. [I; R1 = C4-12 alkyl, C4-12 alkenyl, C4-12 alkynyl, etc.; R2 = C1-12 alkyl, C4-12 alkenyl, C4-12 alkynyl, etc.; Y = OH, NR9R10, F; R9, R10 = H, COR3, CO2R3, etc.; R3 = H, cycloalkyl, alkyl, etc.], inhibitors of matrix metalloproteinases which are useful in treating osteoarthritis, rheumatoid arthritis, septic arthritis, osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation, or asthma, were prepd. E.g., a 7-step synthesis of I [R1 = 4-PhC6H4; R2 = 4-MeOC6H4SO2CH2; Y = OH] which showed Ki of 0.074 .mu.M and 0.0019 .mu.M against stromelysin and gelatinase, resp.

IT 226419-27-8P 226419-34-7P 226419-35-8P

226419-57-4P 226419-58-5P 226419-59-6P

226419-60-9P 226419-61-0P 226419-62-1P

226419-63-2P 226419-95-0P 226419-96-1P

226419-97-2P 226419-98-3P 226419-99-4P


226420-00-4P 226420-01-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of .alpha.-hydroxy, -amino, and halo derivs. of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors)

RN 226419-27-8 HCAPLUS


CN Propanamide, 3-([1,1'-biphenyl]-4-ylsulfonyl)-N,2-dihydroxy-2-[[4-methoxyphenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)



RN 226419-34-7 HCAPLUS

CN Propanamide, 3-([(1,1'-biphenyl]-4-ylsulfonyl)-N,2-dihydroxy-2-([(4-methoxyphenyl)sulfonyl)methyl]-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 226419-35-8 HCAPLUS

CN Propanamide, 3-([(1,1'-biphenyl]-4-ylsulfonyl)-N,2-dihydroxy-2-([(4-methoxyphenyl)sulfonyl)methyl]-, (-)-(9CI) (CA INDEX NAME)


Rotation (-).




RN 226419-57-4 HCAPLUS

CN 1-Imidazolidinepropanamide, .alpha.-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-N,.alpha.-dihydroxy-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 226419-58-5 HCAPLUS  
 CN 1-Imidazolidinepropanamide, 3-butyl-.alpha.-[[ (4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-N,.alpha.-dihydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 226419-59-6 HCAPLUS  
 CN 1-Imidazolidinepropanamide, .alpha.-[[ (4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-N, .alpha.-dihydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI)  
 (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 226419-60-9 HCAPLUS  
 CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N,2-dihydroxy-2-  
 [(phenylthio)methyl]- (9CI) (CA INDEX NAME)




RN 226419-61-0 HCAPLUS  
 CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N,2-dihydroxy-2-  
 [[(phenylmethyl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 226419-62-1 HCAPLUS

CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N,2-dihydroxy-2-[[2-pyridinylmethyl]thio]methyl- (9CI) (CA INDEX NAME)



RN 226419-63-2 HCAPLUS


CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N,2-dihydroxy-2-[[[5-methyl-3-isoxazolyl]methyl]thio]methyl- (9CI) (CA INDEX NAME)




RN 226419-95-0 HCAPLUS

CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-.alpha.-hydroxy-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 226419-96-1 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, 3-butyl-.alpha.-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-.alpha.-hydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 226419-97-2 HCAPLUS  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-.alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 226419-98-3 HCAPLUS  
 CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-  
 [(phenylthio)methyl]- (9CI) (CA INDEX NAME)




RN 226419-99-4 HCAPLUS  
 CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-  
 [[(phenylmethyl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 226420-00-4 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(2-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)



RN 226420-01-5 HCAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[[[(5-methyl-3-isoxazolyl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)




IT 226420-18-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of .alpha.-hydroxy, -amino, and halo derivs. of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors)

RN 226420-18-4 HCAPLUS

CN Propanoic acid, 3-[(1,1'-biphenyl)-4-ylsulfonyl]-2-hydroxy-2-[[[(4-methoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



=&gt;

=&gt;

=&gt; fil reg

FILE 'REGISTRY' ENTERED AT 17:04:36 ON 21 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 OCT 2002 HIGHEST RN 463296-69-7  
DICTIONARY FILE UPDATES: 20 OCT 2002 HIGHEST RN 463296-69-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

=>

=> d reg 17 1-100

1	RN	341499-04-5	REGISTRY
2	RN	341499-01-2	REGISTRY
3	RN	341498-98-4	REGISTRY
4	RN	341498-95-1	REGISTRY
5	RN	341498-92-8	REGISTRY
6	RN	341498-89-3	REGISTRY
7	RN	341498-84-8	REGISTRY
8	RN	341498-83-7	REGISTRY
9	RN	321586-72-5	REGISTRY
10	RN	321586-68-9	REGISTRY
11	RN	321586-57-6	REGISTRY
12	RN	321585-92-6	REGISTRY
13	RN	321585-90-4	REGISTRY
14	RN	321585-88-0	REGISTRY
15	RN	321585-86-8	REGISTRY
16	RN	321585-84-6	REGISTRY
17	RN	321585-82-4	REGISTRY
18	RN	321585-80-2	REGISTRY
19	RN	321585-78-8	REGISTRY
20	RN	321585-76-6	REGISTRY
21	RN	321585-74-4	REGISTRY
22	RN	321585-72-2	REGISTRY
23	RN	321585-70-0	REGISTRY
24	RN	321585-68-6	REGISTRY
25	RN	321585-66-4	REGISTRY
26	RN	321585-64-2	REGISTRY
27	RN	321585-62-0	REGISTRY
28	RN	321585-60-8	REGISTRY
29	RN	321585-58-4	REGISTRY
30	RN	321585-56-2	REGISTRY
31	RN	321585-54-0	REGISTRY
32	RN	321585-51-7	REGISTRY
33	RN	321585-49-3	REGISTRY
34	RN	321585-47-1	REGISTRY
35	RN	321585-45-9	REGISTRY
36	RN	321585-42-6	REGISTRY
37	RN	321585-40-4	REGISTRY
38	RN	321585-38-0	REGISTRY
39	RN	321585-36-8	REGISTRY
40	RN	321585-34-6	REGISTRY


41	RN	321585-32-4	REGISTRY
42	RN	321585-30-2	REGISTRY
43	RN	321585-28-8	REGISTRY
44	RN	321585-26-6	REGISTRY
45	RN	321585-24-4	REGISTRY
46	RN	321585-22-2	REGISTRY
47	RN	321585-20-0	REGISTRY
48	RN	321585-18-6	REGISTRY
49	RN	321585-16-4	REGISTRY
50	RN	321585-14-2	REGISTRY
51	RN	321585-12-0	REGISTRY
52	RN	321585-10-8	REGISTRY
53	RN	321585-04-0	REGISTRY
54	RN	321585-02-8	REGISTRY
55	RN	321585-00-6	REGISTRY
56	RN	321584-98-9	REGISTRY
57	RN	321584-96-7	REGISTRY
58	RN	321584-94-5	REGISTRY
59	RN	321584-92-3	REGISTRY
60	RN	321584-90-1	REGISTRY
61	RN	321584-88-7	REGISTRY
62	RN	321584-86-5	REGISTRY
63	RN	321584-84-3	REGISTRY
64	RN	321584-82-1	REGISTRY
65	RN	321584-78-5	REGISTRY
66	RN	321584-76-3	REGISTRY
67	RN	321584-74-1	REGISTRY
68	RN	321584-72-9	REGISTRY
69	RN	321584-70-7	REGISTRY
70	RN	321584-64-9	REGISTRY
71	RN	321584-62-7	REGISTRY
72	RN	321584-60-5	REGISTRY
73	RN	321584-58-1	REGISTRY
74	RN	321584-56-9	REGISTRY
75	RN	321584-54-7	REGISTRY
76	RN	321584-51-4	REGISTRY
77	RN	321584-50-3	REGISTRY
78	RN	321584-48-9	REGISTRY
79	RN	321584-46-7	REGISTRY
80	RN	321584-44-5	REGISTRY
81	RN	321584-41-2	REGISTRY
82	RN	321584-39-8	REGISTRY
83	RN	226420-18-4	REGISTRY
84	RN	226420-01-5	REGISTRY
85	RN	226420-00-4	REGISTRY
86	RN	226419-99-4	REGISTRY
87	RN	226419-98-3	REGISTRY
88	RN	226419-97-2	REGISTRY
89	RN	226419-96-1	REGISTRY
90	RN	226419-95-0	REGISTRY
91	RN	226419-63-2	REGISTRY
92	RN	226419-62-1	REGISTRY
93	RN	226419-61-0	REGISTRY
94	RN	226419-60-9	REGISTRY
95	RN	226419-59-6	REGISTRY
96	RN	226419-58-5	REGISTRY
97	RN	226419-57-4	REGISTRY
98	RN	226419-35-8	REGISTRY
99	RN	226419-34-7	REGISTRY
100	RN	226419-27-8	REGISTRY

=&gt;

=>  
=> d ide can 17 1 3 9 12 15 20 25 30 35 40 45 50 56 60 65 70 75 80 83 86 90 95 100

L7 ANSWER 1 OF 100 REGISTRY COPYRIGHT 2002 ACS  
 RN 341499-04-5 REGISTRY  
 CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-  
 [(phenylthio)methyl]-, magnesium salt (2:1), (2R)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C22 H19 Cl O5 S2 . 1/2 Mg  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER  
 CRN (341498-83-7)

Absolute stereochemistry.




● 1/2 Mg

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:5449

L7 ANSWER 3 OF 100 REGISTRY COPYRIGHT 2002 ACS  
 RN 341498-98-4 REGISTRY  
 CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-  
 [(phenylthio)methyl]-, monopotassium salt, (2R)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C22 H19 Cl O5 S2 . K  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER  
 CRN (341498-83-7)

Absolute stereochemistry.




● K

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 135:5449

L7 ANSWER 9 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321586-72-5 REGISTRY  
CN 1-Imidazolidinepropanoic acid, 3-butyl-.alpha.-[[ (4'-chloro[1,1'-biphenyl]-4-yl)thio]methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C23 H25 Cl N2 O4 S  
SR CA  
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 12 OF 100 REGISTRY COPYRIGHT 2002 ACS

RN 321585-92-6 REGISTRY

CN 1-Imidazolidinepropanoic acid, .alpha.-[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-5-(hydroxymethyl)-2,4-dioxo- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C21 H19 N3 O7 S

SR CA

LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A






## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 15 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321585-86-8 REGISTRY  
CN Propanoic acid, 2-[[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C23 H20 N2 O4 S2  
SR CA  
LC STN Files: CA, CAPLUS




## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 20 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321585-76-6 REGISTRY  
CN Propanamide, 3-[[[4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C23 H20 N2 O4 S2  
SR CA  
LC STN Files: CA, CAPLUS



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252


L7 ANSWER 25 OF 100 REGISTRY COPYRIGHT 2002 ACS

RN 321585-66-4 REGISTRY  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-5-(hydroxymethyl)-3-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C21 H21 Cl N2 O7 S  
 SR CA  
 LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252


L7 ANSWER 30 OF 100 REGISTRY COPYRIGHT 2002 ACS  
 RN 321585-56-2 REGISTRY  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-3-ethyl-2,5-dioxo- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD

MF C21 H21 Cl N2 O6 S  
SR CA  
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 35 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321585-45-9 REGISTRY  
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[[1,4-dihydro-6-hydroxy-4-oxo-2-pyrimidinyl]thio]methyl- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C20 H17 Cl N2 O6 S2  
SR CA  
LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 40 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321585-34-6 REGISTRY  
CN Propanoic acid, 2-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-[(5-phenyl-1,3,4-oxadiazol-2-yl)thio]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C24 H19 Cl N2 O5 S2  
SR CA  
LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 45 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321585-24-4 REGISTRY  
CN Propanamide, 3-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N-hydroxy-2-[(2-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C21 H19 Cl N2 O4 S2  
SR CA  
LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 50 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321585-14-2 REGISTRY  
CN Propanoic acid, 2-[[4-(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(phenylthio)-, (2R)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C22 H19 Cl O4 S2  
SR CA  
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 56 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321584-98-9 REGISTRY  
CN Propanoic acid, 3-[4-(acetylamino)phenoxy]-2-[[4-(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C24 H22 Cl N O6 S  
SR CA  
LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 60 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321584-90-1 REGISTRY  
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[(2,6-dimethyl-4-pyrimidinyl)thio]methyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C22 H21 Cl N2 O4 S2  
SR CA  
LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 65 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321584-78-5 REGISTRY  
CN Propanoic acid, 2-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3-(2-pyridinylthio)]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C21 H18 Cl N O4 S2  
SR CA  
LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 134:131252

L7 ANSWER 70 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 321584-64-9 REGISTRY  
CN 1-Imidazolidinepropanoic acid, 3-butyl-.alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-2,5-dioxo- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C23 H25 Cl N2 O6 S  
SR CA  
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1962 TO DATE)

## 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 134:131252

L7 ANSWER 75 OF 100 REGISTRY COPYRIGHT 2002 ACS  
 RN 321584-54-7 REGISTRY  
 CN 1-Imidazolidinepropanamide, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-N-hydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C22 H24 Cl N3 O6 S  
 SR CA  
 LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252



L7 ANSWER 80 OF 100 REGISTRY COPYRIGHT 2002 ACS  
 RN 321584-44-5 REGISTRY  
 CN Propanoic acid, 2-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-3-(phenylthio)-, (2S)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C22 H19 Cl O4 S2  
 SR CA  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:131252

L7 ANSWER 83 OF 100 REGISTRY COPYRIGHT 2002 ACS  
 RN 226420-18-4 REGISTRY  
 CN Propanoic acid, 3-([1,1'-biphenyl]-4-ylsulfonyl)-2-hydroxy-2-[[[4-methoxyphenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C23 H22 O8 S2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 131:18833

L7 ANSWER 86 OF 100 REGISTRY COPYRIGHT 2002 ACS  
 RN 226419-99-4 REGISTRY  
 CN Propanoic acid, 3-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[[[phenylmethyl)thio]methyl]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C23 H21 Cl O5 S2

SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 131:18833

L7 ANSWER 90 OF 100 REGISTRY COPYRIGHT 2002 ACS  
 RN 226419-95-0 REGISTRY  
 CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-.alpha.-hydroxy-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C20 H19 Cl N2 O7 S  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 2-A




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 131:18833

L7 ANSWER 95 OF 100 REGISTRY COPYRIGHT 2002 ACS  
RN 226419-59-6 REGISTRY  
CN 1-Imidazolidinepropanamide, .alpha.-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-N,.alpha.-dihydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI)  
(CA INDEX NAME)  
FS 3D CONCORD  
MF C22 H24 Cl N3 O7 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 131:18833

L7 ANSWER 100 OF 100 REGISTRY COPYRIGHT 2002 ACS

RN 226419-27-8 REGISTRY


CN Propanamide, 3-([1,1'-biphenyl]-4-ylsulfonyl)-N,2-dihydroxy-2-[[4-methoxyphenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C23 H23 N O8 S2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 131:18833